Figure 3.

Mean number of claims for facility visits, before and after the index date, for patients with data available for (A) adult patients who switched from eculizumab to ravulizumab, and (B) adult patients receiving treatment with ravulizumab or eculizumab only. ^aP < 0.05 [only analyzed for 0-3 months preindex vs 0-3 months postindex (red asterisks), and for 0-3 months preindex vs 3-6 months postindex (green asterisks)]. Owing to the small sample size, no inferential statistical analysis is reported for patients receiving ravulizumab only. Outcomes analyses required at least 6 months of continued eculizumab or ravulizumab use after the index date. The n values vary owing to the number of patients in each time window with data available. Any claim, not just aHUS-related claims, within the 3-month time window with an associated site-of-care variable were included in this analysis. ER, emergency room.